Transgenic autologous T-cell therapy in humans, and related compositions and kits
OwnerGeoff Symonds, Janet Macphersoninventors
Life of this patent
Estimating the term…
Abstract
This invention provides a method of treating a subject afflicted with a disorder characterized by the presence of a unique epitopic locus in the subject, wherein there exists a therapeutic protein which is capable of ameliorating the effects of the disorder. This invention also provides a related pharmaceutical composition and kit.
Claims14
A method of treating a human subject afflicted with a disorder characterized by the presence of a unique epitopic locus in the subject, wherein there exists a therapeutic protein which is capable of ameliorating the effects of the disorder, the method comprising the steps of
- (a) isolating CD4+ cells from the subject;
- (b) treating the isolated CD4+ cells so as to enrich the population of cells therein which specifically bind to the unique epitopic locus;
- (c) forming transgenic CD4+ cells by introducing into the treated CD4+ cells a nucleic acid molecule encoding the therapeutic protein, wherein the nucleic acid molecule is stably transmitted to progeny CD4+ cells and causes the expression and extracellular placement of the therapeutic protein;
- and
- (d) administering to the subject a therapeutically effective dose of the resulting transgenic CD4+ cells.
A pharmaceutical composition for treating a subject afflicted with a disorder characterized by the presence of a unique epitopic locus in the subject, wherein there exists a therapeutic protein capable of ameliorating the effects of the disorder, the composition comprising
- (a) CD4+ cells derived from the subject which specifically bind to the unique epitopic locus, and which have introduced thereinto a nucleic acid molecule encoding the therapeutic protein, wherein the nucleic acid molecule is stably transmitted to progeny CD4+ cells and causes the expression and extracellular placement of the therapeutic protein;
- and
- (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.